Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial
(WorldNews Denmark)

Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced the headline results from a 52-week double-blind phase 2 clinical trial with once-daily subcutaneous semaglutide investigating safety and potential for inducing and maintaining weight loss in people with obesity. In the trial, 957 people with obesity were randomised to treatment with doses of semaglutide between 0.05 to 0.4 mg/day or placebo. Liraglutide 3.0 mg/day was included for...